ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay ...

ANGLE has also successfully completed its contract with the global pharmaceutical company, Eisai Inc. ("Eisai") demonstrating the ability to measure HER2 CTC ... the assays to test blood samples ...

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary - Now that World Cancer Day (Feb.

In prostate cancer, it is testing its phase 3 cancer vaccine candidate CAN-2409 ... The B-cell cancer vaccines are meant to induce antibody production against proteins like HER2 and PD-1, which can in ...

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, RAS/RAF/MEK1/2/ERK1/2, MAPK, HER2, PI3K/Akt/mTOR, Wnt/β-catenin, NF-κB ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

It brings the anti-HER2 antibody-drug conjugate (ADC) earlier in the treatment pathway for patients with ... approval "highlights the importance of testing metastatic breast cancer tumours for ...

The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These ...

Overactive bladder is a chronic condition that affects 10–45% of women worldwide;1 however, more than half of women discontinue conservative and medical treatment.2,3 Predicting which women are better ...

At-home tests for men worried about prostate cancer can give inconsistent and inaccurate results, BBC News has found. The tests, which resemble a Covid lateral flow strip, turn positive if a high ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies ... in 624 patients with ER+/HER2- advanced or metastatic breast ...